Tyrosinemia

Elevated blood tyrosine levels are present in several clinical entities. The term tyrosinemia is used to describe several syndromes. In general, the association of liver and renal failure, marked peripheral edema, epistaxis, and distinctive cabbage-like odor are characteristic of the disease. There are three types of tyrosinemia-related syndromes.

Tyrosinemia type I: Hepatorenal Tyrosinemia; Fumarylacetoacetase Deficiency; FAH Deficiency.

Tyrosinemia type II: Oculocutaneous Tyrosinemia; Tyrosine Transaminase Deficiency; Tyrosine Aminotransferase Deficiency; Richner-Hanhart Syndrome; Oregon type Tyrosinemia.

Tyrosinemia type III: 4-Hydroxyphenylpyruvic Acid Oxydase Deficiency; 4-Hydroxyphenylpyruvate Dioxygenase Deficiency.

In the United States, the estimated incidence is 1:100,000 live births. However, most cases are seen in the French-Canadian population of the Province of Quebec, with an incidence of carriers of a specific mutation in 1:14 of the adult population and symptomatic presentation in 1:1850 newborns.

Autosomal recessive in all cases. The sex distribution is equal.

Deficiency of fumarylacetoacetate hydrolase results in a moderate rise in serum tyrosine. Metabolites of tyrosine, including succinylacetone, are thought to be the cause of liver, renal, and neurological damage. Transient tyrosinemia is believed to be the result of delayed enzyme maturation in the tyrosine catabolic pathway. Because it is not caused by a genetic mutation, it does not fall into the category of inborn errors of metabolism. In the hereditary infantile tyrosinemia (type I) form, postmortem examination reveals the presence of severe liver and kidney nodular cirrhosis.

Succinylacetone and succinylacetoacetate in blood and urine are diagnostic. Enzyme deficiency demonstrable in liver biopsy specimen or cultured fibroblasts.

Transient tyrosinemia of the newborn is benign and disappears spontaneously with no sequelae.

Hereditary Infantile Tyrosinemia (type I) is a severe form of tyrosinemia. Patients present with peculiar (cabbage-like) odor, renal tubular dysfunction (Fanconi Syndrome), and have a survival rate of fewer than 12 months of life. Fulminant onset of liver failure occurs in the first few months of life. Occasional cases have a later onset; however, the patient is usually younger than age 6 months. This acute form presents with failure to thrive and severe vomiting. Progressive hepatic failure results in death before 2 years of age.

Richner-Hanhart Syndrome (Tyrosinemia type II) is distinctly different with herpetiform corneal ulcers and hyperkeratotic lesions of the tongue, digits, palms, and soles, as well as mental retardation. Most patients are photophobic in bright light. In this more chronic from, deterioration may not occur after first year of life. Patients fail to thrive and develop liver cirrhosis, renal tubular dysfunction, and vitamin D-resistant rickets. Episodes of polyneuropathy, which often cause severe pain, occur in some patients. Death occurs by age 10 years from hepatic failure or hepatoma. Patients are typically chronically anemic and have a coagulopathy secondary to liver failure. They are most often on protein-restricted diet or phenylalanine-restricted diet.

Tyrosinemia type III is an extremely rare cause of ...

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

## Subscription Options

### AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more